In a significant development for Indoco Remedies , the Kare Family Private Trust has completed a substantial share acquisition through off-market transfers dated December 26, 2025. The transaction, executed as part of family succession planning, involved the transfer of shares from Aruna Suresh Kare to the trust without any monetary consideration.

Transaction Details

The regulatory disclosure filed on December 30, 2025, reveals the completion of a major intra-promoter share transfer. The Kare Family Private Trust acquired 55.34 lakh shares representing 6.00% of Indoco Remedies' total share capital from Aruna Suresh Kare through off-market transfer.

Current Shareholding Pattern

Following the completion of this transaction, the Kare Family Private Trust now holds a consolidated position in Indoco Remedies. The trust's shareholding structure demonstrates a strategic consolidation of family assets.

Family Trust Structure

The Kare Family Private Trust was established on November 22, 2024, specifically for smooth succession planning and streamlining family assets and businesses. The trust structure includes Suresh Govind Kare and Aruna Suresh Kare as settlors, while Aditi Milind Panandikar and Madhura Suresh Kare serve as beneficiaries. All parties involved are existing promoters of Indoco Remedies.

Regulatory Compliance

The transaction has been executed in full compliance with SEBI regulations, with appropriate disclosures made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company's equity share capital remains unchanged at ₹18.45 crores, divided into 9.22 crore equity shares of ₹2 each.

Market Impact

This intra-promoter transfer represents a private family arrangement and does not alter the overall promoter shareholding percentage in Indoco Remedies. The transaction strengthens the family's succession planning framework while maintaining the existing control structure of the pharmaceutical company.

Indoco Remedies Limited , a prominent player in the Indian pharmaceutical sector, has reported a notable 8.8% year-on-year growth in standalone net revenues for the second quarter. The company's financial results indicate a gradual recovery after facing challenges due to plant shutdowns in the previous year.

Financial Highlights

• Standalone net revenues reached INR 4,293.00 million in Q2, up from INR 3,946.00 million in the same quarter last year.
• Consolidated revenues increased by 9.6% to INR 4,718.00 million, compared to INR 4,307.00 million in Q2 of the previous year.
• Standalone EBITDA margin stood at 12.4% (INR 534.00 million), slightly lower than the 13.4% reported in the previous year.

Segment Performance

Key Developments

1. Product Launches: Indoco introduced 6 new products in the Indian market during Q2, including Vepazil (anti-infective) and TuspelAA for COPD conditions.

2. Regulatory Compliance: The U.S. FDA completed an inspection of the company's API manufacturing facility at Patalganga with zero observations, a positive development for Indoco's regulatory standing.

3. ANDA Approval: The company received final ANDA approval from the U.S. FDA for Rivaroxaban tablets, expanding its product portfolio in the U.S. market.

4. Manufacturing Efficiency: Management highlighted that investments in manufacturing capability enhancement have started yielding results, leading to higher productivity and competitive cost advantages.

Management Commentary

Aditi Panandikar, Managing Director of Indoco Remedies, expressed confidence in the company's trajectory, stating, "Q2 is the first quarter when we begin to show an uptick in performance. And most importantly, we are finally coming out of the lows of the earlier half year."

She further added, "I'm confident that with an increase in revenues going forward, with the continued control on costs and a focus on efficiency, which we -- all of which are currently being practiced in the company, we will soon go back to the days when we deliver a healthy and consistent financial performance going forward."

Outlook

While Indoco Remedies faces ongoing challenges, particularly in its U.S. operations due to regulatory issues, the company appears to be on a path to recovery. The management's focus on increasing efficiency, controlling costs, and expanding its product portfolio may help in sustaining the growth momentum in the coming quarters.

Investors and market observers will likely keep a close watch on the company's progress in resolving regulatory challenges and its ability to capitalize on opportunities in both domestic and international markets.

About Indoco Remedies Limited

Indoco Remedies Limited is an Indian pharmaceutical company known for its presence in domestic and international markets. The company operates across various segments including domestic formulations, international formulations, and API business, with a growing focus on the U.S. and emerging markets.